IP Library › Granted Patent US 11,628,237
Granted Patent B2
US 11,628,237 · App. 16/033,803 · Granted Apr 18, 2023

Collagen compositions and uses for biomaterial implants

Inventor: Carl Randall Harrell (Tarpon Springs, FL)
Assignee: MAM Holdings of West Florida, L.L.C.
A61L27/24A61K35/50A61K38/39A61K45/06A61L27/362A61L27/3604A61L27/3687A61L27/3804A61L27/54A61L27/60A61L2400/06A61L2430/18A61L2430/34A61L2430/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,628,237
App. No.
16/033,803
Granted
Apr 18, 2023
Kind
B2
Abstract

Compositions containing purified collagen biomaterial derived from tissues, for example, insoluble amnion, soluble amnion, soluble chorion of the human placenta, are provided. The collagen compositions can be used to promote wound healing, promote tissue regeneration, prevent or reduce scarring, reduce local inflammation, minimize tissue rejection, promote graft integration. Methods for using the collagen composition as a biomaterial implant for dermal filling, skin grafting, and hair transplantation are also provided.

Claims (24)

1. A composition for tissue repair or wound healing comprising:

Type I human atelocollagen and Type III human atelocollagen in an amount effective to promote wound healing at a site of surgery, injury, or wound relative to an untreated control;

wherein the total collagen present in the composition comprises about 50% Type I human atelocollagen and about 50% Type III human atelocollagen;

wherein the Type I human atelocollagen and the Type III human atelocollagen are derived from a source of collagen comprising insoluble amnion from human placenta, soluble amnion from human placenta, and soluble chorion from human placenta, or a combination thereof;

wherein the Type I human atelocollagen and Type III human atelocollagen are extracted through proteolytic digestion by treating the source of collagen with pepsin, such that the source of collagen undergoes fission at one or more intermolecular crosslinks and becomes soluble in dilute acids; and

wherein the proteolytic digestion digests one or more telopeptide groups on the source of collagen, thereby leaving the Type I human atelocollagen and the Type III human atelocollagen with no telopeptide terminal ends.

2. The composition of claim 1 , wherein the Type I human atelocollagen and the Type III human atelocollagen is derived from collagen extracted from the human placental tissue without the use of an alkaline solution.

3. The composition of claim 1 , wherein the composition further comprises Collagen Type IV, Collagen Type VII, Collagen Type XVII, elastin, laminin, a proteoglycan, an adhesion protein, or a combination thereof.

4. The composition of claim 1 , wherein the Type I human atelocollagen and the Type III human atelocollagen are sterilized by exposure to 8 kGy of radiation, resulting in a sterility assurance level of 10 6 SAL.

5. The composition of claim 1 , wherein the composition is exposed to 0.25 mRads of radiation to manufacture a skin material.

6. The composition of claim 1 , further comprising one or more compounds selected from the group consisting of antibacterial compounds, antifungal compounds, anti-inflammatory agents, growth factors, or a combination thereof.

7. The composition of claim 1 , further comprising one or more cells selected from the group consisting of stem cells, epidermal stem cells, dermal stem cells, placenta stem cells, and cord blood stem cells, hair follicle cells, or a combination thereof.

8. The composition of claim 1 , further comprising a pharmaceutically acceptable excipient for injection.

9. The composition of claim 1 , wherein the composition is diluted with saline or buffer.

10. The composition of claim 1 , wherein the composition is formulated into a gel, paste, solution or suspension.

11. The composition of claim 1 , wherein the composition is formulated as a hydrogel.

12. A method for promoting wound healing, promoting tissue regeneration, reducing scarring, reducing local inflammation, or improving cosmetic appearance comprising:

administering to a subject in need thereof an effective amount of the composition of claim 1 .

13. The method of claim 12 , wherein the composition is injected at a site of surgery, injury, or wound.

14. The method of claim 12 , wherein the composition is topically applied at a site of surgery, injury, or wound.

15. The method of claim 12 , wherein the composition is administered to the subject to fill wrinkles, lines, folds, scars, or to enhance dermal tissue.

16. The method of claim 12 , wherein the composition is administered to the subject to restore head hair, body hair, eyelashes, eyebrows, or beard hair, or to fill in scars.

17. The method of claim 12 , wherein the composition is administered to the subject at a site of injury, wherein the injury is due to physical, chemical, mechanical, electrical, heat, sunlight, or radiation damage.

18. The method of claim 12 , further comprising repeating the administration of the composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2018
From: HARRELL, CARL RANDALL
To: MAM HOLDINGS OF WEST FLORIDA, L.L.C.
Reel/Frame 047865/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 28, 2018
From: HARRELL, CARL RANDALL
To: MAM HOLDINGS OF WEST FLORIDA, L.L.C.
Reel/Frame 047254/0826 →
Continuity (6)
Continuation 15069537 · Mar 14, 2016
Continuation In Part 13798742 · Mar 13, 2013
Provisional Application 62132571 · Mar 13, 2015
Provisional Application 62132559 · Mar 13, 2015
Provisional Application 61610570 · Mar 14, 2012
Related Publication 20190015548A1 · Jan 17, 2019